A phase II study investigating safety and efficacy of dose reduced fludarabine, cyclophosphamide and obinutuzumab versus chlorambucil and obinutuzumab in untreated, comorbid, elderly patients with chronic lymphocytic leukemia (CLL)

被引：0
|
作者：
Mulligan, Stephen [1 ,2 ]
Tam, Constantine [1 ,2 ]
Badoux, Xavier [1 ,2 ]
Kuss, Bryone [1 ,2 ]
机构：
[1] Australasian Leukaemia & Lymphoma Grp, Richmond, VI, Australia
[2] CLL Australian Res Consortium, Richmond, VI, Australia
来源：
LEUKEMIA & LYMPHOMA | 2015年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
32
引用
收藏
页码：25 / 26
页数：2
相关论文
共 50 条
  • [31] LOW DOSE ORAL FLUDARABINE PLUS CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH UNTREATED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
    Forconi, F.
    Fabbri, A.
    Lenoci, M.
    Sozzi, E.
    Bocchia, M.
    Gozzetti, A.
    Tassi, M.
    Raspadori, D.
    Lauria, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 37 - 37
  • [32] A phase I/II study of the SYK inhibitor entospletinib in combination with obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)
    Kittai, Adam
    Hashiguchi, Taylor
    Thurlow, Bria
    Gokcora, Basak
    Stadnik, Andrzej
    MacKinnon, Renee
    Stephen, Monette
    Moore, Lacey
    Persky, Daniel
    Park, Byung
    Spurgeon, Stephen
    Danilov, Alexey
    LEUKEMIA & LYMPHOMA, 2020, 61 : 76 - 77
  • [33] RESULTS OF A PHASE II MULTICENTER STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE IN PTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
    Danilov, A.
    Yimer, H.
    Boxer, M.
    Di Bella, N.
    Babu, S.
    Li, J.
    Mun, Y.
    Skettino, S.
    Sharman, J.
    HAEMATOLOGICA, 2017, 102 : 71 - 71
  • [34] The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia
    Al-Sawaf, Othman
    Fuerstenau, Moritz
    Giza, Adam
    Robrecht, Sandra
    Von Tresckow, Julia
    Fink, Anna Maria
    Simon, Florian
    Tausch, Eugen
    Schneider, Christof
    Sivcheva, Liliya
    Schwarer, Anthony
    Loscertales, Javier
    Weinkove, Robert
    Strumberg, Dirk
    Kilfoyle, Allanah R.
    Juliusson, Gunnar
    Da Cunha-Bang, Caspar
    Illmer, Thomas
    Gregor, Michael
    Thornton, Patrick
    Janssens, Ann
    Tadmor, Tamar
    Lindstrom, Vesa
    Staber, Philipp Bernhard
    Levin, Mark-David
    Wendtner, Clemens-Martin
    Kreuzer, Karl-Anton
    Ritgen, Matthias
    Stilgenbauer, Stephan
    Kater, Arnon P.
    Niemann, Carsten Utoft
    Fischer, Kirsten
    Eichhorst, Barbara F.
    Hallek, Michael
    BLOOD, 2023, 142
  • [35] LOW DOSE ORAL FLUDARABINE PLUS CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH UNTREATED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (RETROSPECTIVE STUDY)
    Ionita, H.
    Ionita, I.
    Nicola, D. E.
    Pacurar, R.
    Ionita, C. O.
    Cheveresan, M.
    Borzak, G.
    Ionita, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 523 - 524
  • [36] ELEVATE TN: Phase 3 Study of Acalabrutinib Combined With Obinutuzumab or Alone vs Obinutuzumab Plus Chlorambucil in Patients With Treatment-Naive Chronic Lymphocytic Leukemia
    Awan, Farrukh T.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 2 - 4
  • [37] Obinutuzumab and Chlorambucil Versus Chlorambucil Monotherapy for Treatment of Previously Untreated Chronic Lymphocytic Leukemia Where Fludarabine-Based Chemotherapy Is Considered Inappropriate: A Canadian Cost-Utility Analysis
    Cameron, Heather
    Thompson, Melissa
    Marino, John-Paul
    Duong, Michael
    Becker, Ursula
    Wiesner, Christof
    BLOOD, 2014, 124 (21)
  • [38] Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom
    Sinha, Richa
    Redekop, William Ken
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (02): : E131 - E142
  • [39] Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia
    Byrd, John C.
    Flynn, Joseph M.
    Kipps, Thomas J.
    Boxer, Michael
    Kolibaba, Kathryn S.
    Carlile, David J.
    Fingerle-Rowson, Guenter
    Tyson, Nicola
    Hirata, Jamie
    Sharman, Jeff P.
    BLOOD, 2016, 127 (01) : 79 - 86
  • [40] Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations
    Nitin Jain
    Philip Thompson
    Jan Burger
    Alessandra Ferrajoli
    Koichi Takahashi
    Zeev Estrov
    Gautam Borthakur
    Prithviraj Bose
    Tapan Kadia
    Naveen Pemmaraju
    Koji Sasaki
    Marina Konopleva
    Elias Jabbour
    Naveen Garg
    Xuemei Wang
    Rashmi Kanagal-Shamanna
    Keyur Patel
    Wei Wang
    Jeffrey Jorgensen
    Sa Wang
    Wanda Lopez
    Ana Ayala
    William Plunkett
    Varsha Gandhi
    Hagop Kantarjian
    Susan O’Brien
    Michael Keating
    William G. Wierda
    Leukemia, 2021, 35 : 3421 - 3429
12345